Meta-Analysis
Copyright ©The Author(s) 2020.
World J Cardiol. Nov 26, 2020; 12(11): 559-570
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.559
Table 2 Percentage prevalence of co-morbidities across studies (actual prevalence in brackets)
Ref.Damluji et al[12]1Flores-Umanzor et al[13]Yan et al[15]Choi et al[14]
OMT (n = 490)ER (n = 482)OMT (n = 326)EREROMT (n = 118)ER (n = 118)OMT (n = 318)ER (n = 384)
PCI (n = 76)CABG (n = 136)
HTN80 (385)81 (387)85 (276)82 ( 62)86 (117)66.9 (79)71.2 (84)70.7 (225)70.3 (270)
Previous MI44 (214)41 (197)33 (108) 28 (21)28 (21)56.8 (67)55.9 (66)34.9 (111)18.0 (69)
Prior CHF7 (36)9 (43)---14.4 (17)10.2 (12)--
Prior Stent/PCI11 (56)12 (59)---48.3 (57)42.4 (50)30.5 (97)22.1 (85)
Prior CVA/TIA10 (49)10 (46)---5.1 (6)5.9 (7)12.3 (39)11.2 (43)
Prior Revascularizatio31 (151)26 (124)-------
Prevnious CABG--14 (45)5 (4)4 (5)--00
HbA1c mean7.47.37.6 ± 0.17.6 ± 0.27.3 ± 0.1----
Dyslipidemia83 (402)84 (400)75 (246)71 (54)74 (100)51.7 (61)50 (59)21.7 (69)31.3 (120)
Smoking--52 (169)55 (42)59 (80)55.9 (66)57.6 (68)28.6 (91)32.8 (126)
Peripheral vascular disease--45 (145)33 (25)35 (47)3.4 (4)3.4 (4)6.0 (19)3.4 (13)